Technology
Taking targeted cancer treatment to the next level.
BioSyngen is utilizing our proprietary technology platforms to develop next-generation CAR-T and TCR-T therapies to target unmet medical needs.
In activating a strong immune response, our therapies not only destroy cancer cells but also critically reduce off-target or on target off tumor toxicities to preserve healthy cells,—ensuring enhanced safety and clinical efficacy in tandem.
Fast identification of tumor antigens and their antagonizing agents.
Our IDENTIFIER platform allows us to identify the most unique and suitable tumor antigens and perform fast screening of antibodies and T cell receptors (TCRs) against these antigens.
Blocking barriers in treating solid tumors.
By utilizing the MSE-T platform, our smart immune cells can effectively attack difficult-to-treat solid tumors by better recognizing tumor specific antigens and overcoming immunosuppressive tumor microenvironment.
Conditional activation in tumor microenvironment.
The proprietary SUPER-T platform allows safety enhancement of immunotherapies in general by conditional activation only in tumor microenvironment.
Pipeline
Translating treatments from bench to bedside.
Multiple clinical trials are underway to advance immunotherapy solutions, enabled by BioSyngen’s extensive clinical network and large-scale GMP manufacturing capabilities.
As we strive to create a brighter future for cancer patients and their families, Biosyngen is combining innovative technologieswith medical expertise en route to becoming a visionary biotechunicorn in Singapore and the region.
News
Mar 29, 2023
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, He...
Oct 27, 2023
On October 26, 2023, Biosyngen’s TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy ...
Sep 11, 2023
On September 9th, 2023, Biosyngen Pte Ltd (hereafter as “Biosyngen”) announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric can...
OUR PARTNERS
Copyright © 2023
Biosyngen Pte. Ltd.
Copyright © 2022 Biosyngen Pte. Ltd.
MENU
